Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.26
-12.9%
$0.37
$0.25
$2.58
$16.03M12.60 million shs2.04 million shs
DURECT Co. stock logo
DRRX
DURECT
$0.50
-8.1%
$0.70
$0.49
$1.88
$15.52M0.6688,809 shs248,125 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.30
-1.5%
$3.13
$2.57
$6.88
$20.39M0.599,000 shs2,691 shs
Onconetix, Inc. stock logo
ONCO
Onconetix
$0.07
-0.1%
$0.08
$0.05
$21.40
$4.68M3.497.97 million shs3.49 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-12.93%-23.57%-40.95%-47.78%-89.86%
DURECT Co. stock logo
DRRX
DURECT
-8.11%-18.06%-25.34%-37.50%-61.55%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-1.49%+0.61%+8.20%-20.67%-49.54%
Onconetix, Inc. stock logo
ONCO
Onconetix
-0.14%-17.73%+3.58%-77.38%-99.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.0118 of 5 stars
3.53.00.00.02.42.51.3
DURECT Co. stock logo
DRRX
DURECT
0.744 of 5 stars
0.01.00.04.42.70.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.7068 of 5 stars
0.03.00.00.02.21.70.6
Onconetix, Inc. stock logo
ONCO
Onconetix
0.3451 of 5 stars
0.02.00.00.03.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.00
Buy$5.632,076.02% Upside
DURECT Co. stock logo
DRRX
DURECT
2.00
HoldN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ONCO, NAII, CGTX, and DRRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $3.00
5/8/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
3/27/2025
DURECT Co. stock logo
DRRX
DURECT
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/24/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
3/21/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.76 per shareN/A
DURECT Co. stock logo
DRRX
DURECT
$1.86M8.36N/AN/A$0.50 per share1.00
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.16N/AN/A$12.77 per share0.26
Onconetix, Inc. stock logo
ONCO
Onconetix
$1.87M2.50N/AN/A$3.01 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$25.79M-$0.74N/AN/AN/AN/A-150.93%-100.82%8/14/2025 (Estimated)
DURECT Co. stock logo
DRRX
DURECT
-$27.62M-$0.15N/AN/AN/A-198.58%-300.62%-65.17%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.26%-9.36%-4.82%N/A
Onconetix, Inc. stock logo
ONCO
Onconetix
-$37.41MN/A0.00N/A-2,758.89%N/A-48.09%6/2/2025 (Estimated)

Latest ONCO, NAII, CGTX, and DRRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/6/2025Q1 2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.12-$0.14-$0.02-$0.14N/AN/A
3/26/2025Q4 2024
DURECT Co. stock logo
DRRX
DURECT
$0.06-$0.06-$0.12$0.24$6.91 million$2.30 million
3/20/2025Q4 2024
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.16-$0.17-$0.01-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
DURECT Co. stock logo
DRRX
DURECT
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
2.11
2.11
DURECT Co. stock logo
DRRX
DURECT
N/A
0.71
0.60
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A
0.06
0.05

Institutional Ownership

CompanyInstitutional Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
DURECT Co. stock logo
DRRX
DURECT
28.03%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Onconetix, Inc. stock logo
ONCO
Onconetix
23.89%

Insider Ownership

CompanyInsider Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
20.75%
DURECT Co. stock logo
DRRX
DURECT
3.20%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Onconetix, Inc. stock logo
ONCO
Onconetix
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2061.99 million32.93 millionNot Optionable
DURECT Co. stock logo
DRRX
DURECT
8031.04 million30.05 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.90 millionNot Optionable
Onconetix, Inc. stock logo
ONCO
Onconetix
1264.55 million57.17 millionN/A

Recent News About These Companies

Onco-Innovations Uplists to Cboe Canada
Onco-Innovations Announces Private Placement
Onco-Innovations Extends Marketing Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$0.26 -0.04 (-12.93%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.27 +0.01 (+4.45%)
As of 06:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

DURECT stock logo

DURECT NASDAQ:DRRX

$0.50 -0.04 (-8.11%)
As of 05/27/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.38 +0.03 (+0.75%)
As of 05/27/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Onconetix stock logo

Onconetix NASDAQ:ONCO

$0.07 0.00 (-0.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.07 0.00 (-1.66%)
As of 06:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.